InnoCan Pharma
Cannabinoid-integrated Pharmaceutical Products
StartupInnoCan Pharma is a Herzliya-based startup in the Health Tech & Life Sciences sector, established in 2017. Cannabinoid-integrated Pharmaceutical Products. The company has raised a total of $23.67M across 13 funding rounds, currently at the Public stage. InnoCan Pharma was founded by Ron Mayron, Iris Bincovich, Nir Avram, Yoram Drucker. Key investors include Tamar Innovest, Undisclosed Investor(s), Invicta Ventures, among 4 total investors. The company has 11-50 employees. Core technologies: Biologicals, Cells, Herbals.
With $23.67M in total funding, InnoCan Pharma is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C/B2C/B2B business model. Product stage: Released. The company holds 1 patent.
- StagePublic
- ProductReleased
- ModelB2B2C, B2C, B2B
- Employees11-50
- HQHerzliya
- DistrictCenter District
- Last Round$155K
- Tamar Innovest
- Undisclosed Investor(s)
- Invicta Ventures
4 investors total
Ron MayronFounder & Executive ChairmanIris BincovichFounder & CEO
Nir AvramFounder & CTO
Yoram DruckerFounder (No longer with the company)
176 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
www.newsfilecorp.com,
www.businesswire.com,
vnexplorer.net.
What does InnoCan Pharma do?
Innocan Pharma is a pharmaceutical technology company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprised of cannabinoids science to treat various conditions and improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform, which facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream; the LPT delivery platform research is in the preclinical trial phase for two indications: epilepsy and pain management; and (ii) CLX CBD-loaded exosomes platform, which aims to target the central nervous system through regeneration and by addressing inflammation. In the consumer wellness segment, Innocan develops and markets a wide portfolio of innovative self-care products to promote a healthier lifestyle. Under this segment Innocan has established a joint venture by the name of BI Sky Global Ltd., which focuses on developing advanced targeted online sales.
How much funding has InnoCan Pharma raised?
InnoCan Pharma has raised $23.67M in total funding across 13 rounds. The company is currently at the Public stage. Key investors include Tamar Innovest, Undisclosed Investor(s), Invicta Ventures.
Who founded InnoCan Pharma?
InnoCan Pharma was founded in 2017 by Ron Mayron (Founder & Executive Chairman), Iris Bincovich (Founder & CEO), Nir Avram (Founder & CTO), Yoram Drucker (Founder (No longer with the company)).
What sector is InnoCan Pharma in?
InnoCan Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drug Delivery, Medical Cannabis, with core technologies in Biologicals, Cells, Herbals. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.
Where is InnoCan Pharma located?
InnoCan Pharma is based in HaMenofim Street 10, Herzliya, Israel, Center District.